AMENDMENT #1 TO THE
CLINICAL TRIAL AGREEMENT BETWEEN
VION PHARMACEUTICALS, INC. AND THE
DIVISION OF CANCER TREATMENT AND DIAGNOSIS, NCI
DATED MARCH 2, 2006
The purpose of this
amendment (“Amendment”), effective as of the last date
signed below (“Effective Date”), is to change certain
terms of the above referenced Clinical Trials Agreement (CTA)
(“Agreement”). These changes are reflected below and
except for these changes, all other provisions remain in full force
and effect. Two (2) originals of this amendment are provided
for execution; one is to remain with the National Cancer Institute,
and the second is to remain with Vion Pharmaceuticals.
The CTA shall be amended
to extend the term for conducting clinical studies with this Agent
for a period of two (2) years. The date of expiration of this
CTA is now January 9, 2008.
Capital Technology Information Service.
Article 6. Drug Information and
Article 6 is hereby
amended as follows:
The contact person for
DCTD will be Mr. Charles Hall, Chief,